CompletedN/Aketamine

Ketamine for Acute Migraine in the Emergency Department

NCT ID

NCT02697071

Target Enrollment

34 participants

Start Date

2016-02

Est. Completion

2017-03

About This Study

This research study will be a prospective, randomized, double-blind, placebo-controlled trial. Because ketamine has yet to be directly studied as treatment for acute migraine headache in the emergency department, the research team is initially interested if ketamine can reduce pain scores in headache patients and reduce the incidence of recurrence while exhibiting an adequate safety profile. By using a placebo-controlled study design, the research team can adequately investigate the effectiveness of the medication in a subgroup previously not well studied.

Conditions Studied

Headache

Interventions

•Ketamine
•Normal Saline

Eligibility

Age:18 Years - 65 Years

Healthy Volunteers:Yes

View full eligibility criteria

Inclusion Criteria:

* 18-65 years of age
* Chief complaint of headache
* International Classification of Headache Disorder classification of migraine or probable migraine with or without aura
* Has decision making capacity
* Consent
* Provider determination of non-emergent cause

Exclusion Criteria:

* Over the age of 50 with first time headache
* Known adverse reaction or tolerance to study medication
* Headache due to trauma
* New onset, focal, abnormal, neurologic findings
* New onset seizures
* History of metastatic cancer or neoplasm
* Active psychotic symptoms
* Altered mental status
* Provider intends to preform lumbar puncture
* Pregnancy
* Breast feeding
* Previous enrollment in study
* Fever \> 100.3 F
* Physiologic instability (blood pressure \< 90/50 or \>170/100, heart rate \<50 or \>120, chronic respiratory, renal or hepatic failure)
* Suspected cardiac pain

Study Locations (1)

Carilion Roanoke Memorial Emergency Department

Roanoke, Virginia, United States